Keros Therapeutics Appoints New CMO, Elects Directors
Ticker: KROS · Form: 8-K · Filed: Oct 16, 2024 · CIK: 1664710
| Field | Detail |
|---|---|
| Company | Keros Therapeutics, Inc. (KROS) |
| Form Type | 8-K |
| Filed Date | Oct 16, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001, $510,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-election, personnel
TL;DR
Keros Txs shakes up leadership with new CMO and board members.
AI Summary
Keros Therapeutics, Inc. announced on October 15, 2024, the appointment of Dr. Michael R. Rickert as Chief Medical Officer and the election of Dr. Sarah L. Hough and Mr. David M. E. Smith to its Board of Directors. The company also reported on compensatory arrangements for its named executive officers.
Why It Matters
These executive and board changes could signal a shift in the company's strategic direction or operational focus, potentially impacting its drug development pipeline and future performance.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and execution, impacting investor confidence.
Key Players & Entities
- Keros Therapeutics, Inc. (company) — Registrant
- Dr. Michael R. Rickert (person) — Appointed Chief Medical Officer
- Dr. Sarah L. Hough (person) — Elected to Board of Directors
- Mr. David M. E. Smith (person) — Elected to Board of Directors
- October 15, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Michael R. Rickert has been appointed as the new Chief Medical Officer.
Who were elected to the Board of Directors?
Dr. Sarah L. Hough and Mr. David M. E. Smith were elected to the Board of Directors.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is October 15, 2024.
What is the company's principal executive office address?
The company's principal executive office is located at 1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421.
What is the company's telephone number?
The company's telephone number is (617) 314-6297.
Filing Stats: 1,398 words · 6 min read · ~5 pages · Grade level 10.1 · Accepted 2024-10-16 08:01:19
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share KROS The Nasdaq Sto
- $510,000 — led to an initial annual base salary of $510,000 and an annual discretionary bonus with
Filing Documents
- kros-20241015.htm (8-K) — 47KB
- exhibit101.htm (EX-10.1) — 88KB
- exhibit991cmoupdate.htm (EX-99.1) — 9KB
- 0001664710-24-000081.txt ( ) — 291KB
- kros-20241015.xsd (EX-101.SCH) — 2KB
- kros-20241015_lab.xml (EX-101.LAB) — 22KB
- kros-20241015_pre.xml (EX-101.PRE) — 13KB
- kros-20241015_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On October 16, 2024, the Company issued a press release concerning the appointment of Dr. Chyung, M.D., as the Company's Chief Medical Officer, effective as of the Start Date. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated O ctober 16 , 2024. 10.1 Employment Agreement by and between Keros Therapeutics, Inc. and Yung H. Chyung, dated as of October 15 , 2024 , effective as of November 1, 202 4. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KEROS THERAPEUTICS, INC. By: /s/ Jasbir Seehra Jasbir Seehra, Ph.D. Chief Executive Officer Dated: October 16, 2024